Heteroaryl NaV1.8 Inhibitors for Selective Neuropathic Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing voltage-gated sodium channel inhibitors have limitations such as poor therapeutic window, lack of isoform selectivity, and low potency, making them ineffective for treating various pain conditions, particularly neuropathic pain.
Innovation Solution
Development of selective voltage-gated sodium channel inhibitors, specifically targeting NaV1.8 channels, to inhibit pain signaling and treat conditions like chronic pain, neuropathic pain, and cardiac arrhythmia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing voltage-gated sodium channel inhibitors are used, then pain signaling is inhibited, but therapeutic window is poor and isoform selectivity is lacking
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I, II, III) that target particular sodium channel isoforms (NaV1.8, NaV1.7, NaV1.9) in specific tissue locations. The heteroaryl compounds are structurally optimized to interact selectively with certain isoforms over others, providing localized specificity at the molecular level while maintaining therapeutic efficacy in pain conditions.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the sodium channel inhibitors, including substituent groups (R1-R10, X1-X4, Y1-Y4), chemical formulas, and structural configurations. This allows optimization of binding affinity, selectivity for specific isoforms, and therapeutic window by adjusting chemical parameters to achieve desired pharmacological properties.
2Manufacturing precision
If non-selective sodium channel inhibitors are used, then pain is reduced, but potency is low and adverse events increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I, II, III) that target particular sodium channel isoforms (NaV1.8, NaV1.7, NaV1.9) in specific tissue locations. The heteroaryl compounds are structurally optimized to interact selectively with certain isoforms over others, providing localized specificity at the molecular level while maintaining therapeutic efficacy in pain conditions.
Solution Approach 2:
The patent converts the potential harm of non-selective channel blocking into a benefit by using selective isoform targeting. By designing compounds that preferentially block pain-relevant isoforms (NaV1.8 in peripheral nerves, NaV1.7/1.9 in central neurons) while sparing other isoforms, the therapy achieves high potency for pain relief while minimizing adverse effects from non-specific blocking.
3Adaptability or versatility
If conventional analgesics are used, then acute pain is managed, but chronic pain and neuropathic pain treatment options are limited
Solution Approach 1:
The patent applies universality by developing a series of heteroaryl compounds that can target multiple sodium channel isoforms (NaV1.7, NaV1.8, NaV1.9) with different selectivity profiles. This multi-functional approach allows the same chemical framework to address diverse pain conditions including acute pain, chronic pain, and neuropathic pain by adjusting specific molecular parameters and substituent groups.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the sodium channel inhibitors, including substituent groups (R1-R10, X1-X4, Y1-Y4), chemical formulas, and structural configurations. This allows optimization of binding affinity, selectivity for specific isoforms, and therapeutic window by adjusting chemical parameters to achieve desired pharmacological properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selective inhibitors effectively reduce pain and hyper-excitability by targeting NaV1.8 channels, providing a broader therapeutic window and improved efficacy in treating pain conditions.
Implementation Method 1
Voltage-gated sodium channels (NaVs) are involved in pain signaling. NaVs are biological mediators of electrical signaling as they mediate the rapid upstroke of the action potential of many excitable cell types... antagonists that reduce Nav currents can prevent or reduce neural signaling
Data Source
AI summary
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.